MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Interest Expense 2011-2026 | QTNT
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.72 M | 2.2 M | -6.94 M | 2.37 M | -1.11 M | 3.5 M | -4.06 M | -197 K | 11 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.5 M | -6.94 M | -167 K |
Quarterly Interest Expense Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.6 M | 1.01 M | -19.6 M | - | -3.51 M | 677 K | 4.18 M | 9.5 M | 617 K | 192 K | 5 M | 233 K | 1.89 M | 1.89 M | -1.24 M | 952 K | -1.54 M | -1.54 M | -468 K | - | 33 K | 565 K | 880 K | - | -4.57 M | -1.89 M | 2.68 M | - | 305 K | -987 K | -1.29 M | - | 130 K | -1.49 M | 534 K | - | -45 K | -83 K | 77 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.6 M | -19.6 M | 416 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M |  USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 29.14 | -3.75 % | $ 326 M |  China |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.1 | 0.46 % | $ 1.4 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
106 K | - | - | $ 79.8 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 11.38 | 1.16 % | $ 323 M | Israel |
 |
DexCom
DXCM
|
177 M | $ 70.29 | 8.0 % | $ 27.4 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 103.65 | -1.16 % | $ 4.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 32.89 | 3.09 % | $ 914 M | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 211.14 | -1.74 % | $ 154 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 205.13 | -0.82 % | $ 22.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Fulgent Genetics
FLGT
|
561 K | $ 23.24 | 1.18 % | $ 703 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 19.6 | 2.62 % | $ 1.05 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.85 | - | $ 8.12 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 103.32 | 0.09 % | $ 19.1 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 68.71 | -0.02 % | $ 4.75 B | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 104.76 | 1.95 % | $ 12.9 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
National Research Corporation
NRC
|
862 K | $ 12.09 | -5.81 % | $ 297 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 160.2 | 0.91 % | $ 8.23 B | USA |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 627.58 | 1.68 % | $ 51.8 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 115.9 | 1.27 % | $ 18.4 B | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.24 | 2.48 % | $ 861 M | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 166.72 | -1.27 % | $ 30.2 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 204.66 | -1.53 % | $ 20.1 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 31.11 | -0.94 % | $ 20 B | Niderland |
|
Biodesix
BDSX
|
8.26 M | $ 11.55 | 6.6 % | $ 1.5 B | USA |
 |
Personalis
PSNL
|
24 K | $ 8.22 | -2.09 % | $ 487 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 281.39 | 1.13 % | $ 23.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 95.34 | 19.06 % | $ 7.86 B |  Irlanda |
 |
Biomerica
BMRA
|
367 | $ 2.25 | 4.19 % | $ 5.17 M | USA |
 |
Bioventus
BVS
|
1.29 M | $ 8.22 | 1.48 % | $ 515 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 429.09 | 3.14 % | $ 12.4 B | USA |